Indans

"Indans" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES.

Descriptor ID	D007189
MeSH Number(s)	D02.455.426.559.847.486.487 D04.615.486.487
Concept/Terms	Indans Indans Indanones Indanones

Below are MeSH descriptors whose meaning is more general than "Indans".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Polycyclic Aromatic Hydrocarbons [D02.455.426.559.847]
Indenes [D02.455.426.559.847.486]
Indans [D02.455.426.559.847.486.487]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Indenes [D04.615.486]
Indans [D04.615.486.487]

Below are MeSH descriptors whose meaning is related to "Indans".

Below are MeSH descriptors whose meaning is more specific than "Indans".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Indans" by people in this website by year, and whether "Indans" was a major or minor topic of these publications.

Bar chart showing 14 publications over 10 distinct years, with a maximum of 2 publications in 2004 and 2005 and 2014 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	2	0	2
2005	2	0	2
2006	1	0	1
2010	1	0	1
2011	1	0	1
2013	1	0	1
2014	1	1	2
2018	1	1	2
2024	0	1	1
2025	1	0	1

Below are the most recent publications written about "Indans" by people in Profiles.

Kaur J, Spielvogel E, Nageswara Rao D, Rusere LN, Shaqra AM, Lockbaum GJ, Maryam A, Yilmaz NK, Swanstrom R, Schiffer CA, Ali A. Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2' ligands with potent activity against drug-resistant variants. Eur J Med Chem. 2026 Feb 15; 304:118510.

View in: PubMed
Schuster J, Dreyhaupt J, M?nkem?ller K, Dupuis L, Dieterl? S, Weishaupt JH, Kassubek J, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Johannesen S, G?ricke B, Witzel S, Dorst J, Ludolph AC. In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis. Eur J Neurol. 2024 Apr; 31(4):e16204.

View in: PubMed
Ishikawa T, Okano M, Minami A, Tsunekawa H, Satoyoshi H, Tsukamoto Y, Takahata K, Muraoka S. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity. Behav Brain Res. 2019 02 01; 359:353-361.

View in: PubMed
Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Wolleb?k Johannesen S, G?ricke B. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018 08; 17(8):681-688.

View in: PubMed
Bag S, Tulsan R, Sood A, Cho H, Redjeb H, Zhou W, LeVine H, T?r?k B, T?r?k M. Sulfonamides as multifunctional agents for Alzheimer's disease. Bioorg Med Chem Lett. 2015 Feb 01; 25(3):626-30.

View in: PubMed
Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014 Dec; 34(12):1250-8.

View in: PubMed
Martinez FJ. Long-acting bronchodilators in COPD: an evolving story. Lancet Respir Med. 2013 Sep; 1(7):499-501.

View in: PubMed
Donohue JF, Martinez FJ. Indacaterol. COPD. 2011 Oct; 8(5):327-8.

View in: PubMed
Leegwater-Kim J, Bortan E. The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25; 5:149-56.

View in: PubMed
McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE. C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13; 49(14):4269-74.

View in: PubMed

People

Explore

Similar Concepts

Top Journals